Coronary Artery Disease Progression in Patients With Prediabetes

Coronary Artery Disease Progression by iMap Intravascular Ultrasound Analysis in Patients With Prediabetes

Prediabetes is a disorder of glucose metabolism that reflects the natural history of progression from normoglycaemia to type 2 diabetes mellitus. Patients with prediabetes have impaired glucose regulation caused by insulin resistance (IR). IR in patients undergoing percutaneous coronary intervention (PCI) is associated with coronary artery remodeling and coronary plaque vulnerability by intravascular ultrasound (IVUS) analysis. In stent restenosis after bare metal and drug-eluting stent implantation more frequently is observed in patients with high fasting-insulin levels and IR. Although IR has a significant role in the progression of atherosclerosis in prediabetic patients, the importance of managing prediabetes is often under-appreciated by clinicians. To date, no pharmacological treatment has been officially approved for prediabetes. According to American Diabetes Association recommendations, metformin is the only drug that could be considered in the treatment of prediabetic patients with a high risk of developing diabetes. Metformin is a safe and inexpensive glucose lowering drug that attenuates mortality and future cardiovascular events in patients with type 2 diabetes as well as the progression of atherosclerosis in non-diabetic animal models. This study was designed to analyze coronary plaque characteristics by iMAP IVUS in patients with and without prediabetes undergoing PCI and to evaluate the impact of metformin treatment on coronary plaque characteristics in prediabetic patients at 24 month follow up.

The study hypothesis is that more pronounced coronary atherosclerosis progression as well as in-stent neointimal hyperplasia will be observed in patients with prediabetes. Metformin treatment attenuates the progression of atherosclerosis in patients with prediabetes.

Study Overview

• Status: Completed
• Conditions: Coronary Artery Disease; Atherosclerosis; Prediabetic State
• Intervention / Treatment: Drug: Metformin; Behavioral: Lifestyle recommendations

Detailed Description

Patients undergoing PCI and IVUS pullback for the target vessel will be enrolled in a prospective study. Before PCI and at 24 month follow up fasting blood will be collected for glucose, HbA1c, C peptide, lipid profile assessment. Patients' baseline demographic characteristics, medical history, and procedural data will be collected during the index hospitalization and at 24 month follow up. Patients will be divided in groups according to HbA1c - control group (HbA1c<5.7) and prediabetic patients (HbA1c 5.7-6.4). PCI will be performed in accordance with the guidelines. After successful treatment of the culprit lesion IVUS will be done. Following PCI and IVUS patients with prediabetes will be randomly assigned in groups either receiving metformin at a dose of 2000 mg once daily plus standard lifestyle recommendations or standard lifestyle recommendations only. Intravascular ultrasound analysis will be repeated 24 months after the initial PCI.

• Study Type: Interventional
• Enrollment (Actual): 70
• Phase: Phase 4

Contacts and Locations

Study Locations

• Latvia
  • Riga, Latvia
    • Pauls Stradins Clinical University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• age ≥18 and <75 years;
• patients with stable coronary artery disease referred to PCI in an artery suitable for IVUS pullback;
• signed informed consent before PCI.

Exclusion Criteria:

• cardiac or non-cardiac illness with life expectancy of less than two years;
• failure to advance the IVUS catheter through the culprit lesion;
• acute coronary syndrome
• congestive heart failure (New York Heart Association (NYHA) classification stage III-IV)
• diabetes mellitus
• chronic kidney disease
• previous PCI in the target vessel
• heavily calcified vessels
• allergy to metformin

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Prediabetes, metformin; Patients with HbA1c 5.7-6.4 receiving metformin and lifestyle recommendations	Drug: Metformin; In order to minimize gastrointestinal discomfort, metformin treatment will be started with a dose of 500 mg p/o once daily, then gradually increased to 2000 mg p/o once daily for 24 months; Other Names: Glucophage extended release (XR); Behavioral: Lifestyle recommendations; Standard lifestyle recommendations
Active Comparator: Prediabetes, lifestyle; Patients with HbA1c 5.7-6.4 receiving lifestyle recommendations	Behavioral: Lifestyle recommendations; Standard lifestyle recommendations

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage plaque volume change over 24 months	Changes in plaque volume in 24 months	24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Culprit lesion in-stent restenosis	Neointimal hyperplasia at 24 month follow up	24 months
Plaque tissue component percentage change over 24 months	Percentage change in necrotic, fibrotic, lipidic and calcific tissue volume	24 months
Correlation of glycemic parameters with plaque characteristics	Correlation of glycemic parameters with plaque characteristics	At index hospitalization and follow up (24 months)
Plaque volume change in metformin vs non-metformin treated patients over 24 months	Plaque volume change in metformin vs non-metformin treated patients over 24 months	24 months

Collaborators and Investigators

• Sponsor: Pauls Stradins Clinical University Hospital

Study record dates

Study Major Dates

• Study Start: February 1, 2016
• Primary Completion (Actual): July 31, 2019
• Study Completion (Actual): September 1, 2021

Study Registration Dates

• First Submitted: April 15, 2016
• First Submitted That Met QC Criteria: April 15, 2016
• First Posted (Estimate): April 20, 2016

Study Record Updates

• Last Update Posted (Actual): April 22, 2022
• Last Update Submitted That Met QC Criteria: April 21, 2022
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Keywords: Insulin resistance; Coronary artery disease; Prediabetes; Atherosclerosis; Metformin; Percutaneous coronary intervention; Intravascular ultrasound
• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Glucose Metabolism Disorders; Metabolic Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Endocrine System Diseases; Disease Attributes; Diabetes Mellitus; Hyperglycemia; Coronary Artery Disease; Myocardial Ischemia; Coronary Disease; Disease Progression; Prediabetic State; Glucose Intolerance; Atherosclerosis; Hypoglycemic Agents; Physiological Effects of Drugs; Metformin
• Other Study ID Numbers: IVUS-0216

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No